Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Immunogenicity Study of NWRD09 in HPV16 Related Cervical High-grade Squamous Intraepithelial Lesions (HSlL)

NCT07047989 is registered in ClinicalTrials.gov with Newish Biotech (Wuxi) Co., Ltd. as lead sponsor.

NCT NCT07047989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Immunogenicity Study of NWRD09 in HPV16 Related Cervical High-grade Squamous Intraepithelial Lesions (HSlL)
Lead sponsor
Newish Biotech (Wuxi) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 12, 2025
Completion date
December 31, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade squamous intraepithelial lesion (hsil)